Evaluation of the Efficacy of Therapeutic Infiltrations of the Pudendal Nerve, Performed Under Neurostimulation on Pain, 1 Month After an Infiltration of Local Anaesthetic, in the Treatment of Pudendal Neuralgia.

Last updated: May 16, 2025
Sponsor: Groupe Hospitalier Diaconesses Croix Saint-Simon
Overall Status: Active - Recruiting

Phase

3

Condition

Pain (Pediatric)

Pain

Treatment

Saline Solution for Block

Lidocaine Injectable Solution

Clinical Study ID

NCT06872437
RI-B-2021-7300-07
  • Ages > 18
  • All Genders

Study Summary

Pudendal neuralgia (PN) is a chronic nerve compression syndrome causing neuropathic pain. Treatment includes medication, infiltration and decompressive surgery. Medicinal treatment involves the use of drugs that have proved effective in other areas, such as shingles or diabetes. There is no consensus on the molecules to be used for pudendal nerve infiltration (PNTI), and less than half of patients experience short-term relief. The only risk factor for failure is the duration of pain. Our study proposes to compare the usual treatment with a placebo, as no type of infiltration has been compared with a placebo.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient 18 years of age or older,

  • Expressed consent to participate in the study

  • Affiliated or beneficiary of a social security plan

  • With pudendal neuralgia (Nantes criteria "modified" Nantes criteria).

  • MRI normal or without pathology explaining the pain

  • Drug treatment failure as defined in the LOS, i.e., failure (VAS decrease < 3) of atleast one antiepileptic drug and an antidepressant whose dosages have been to themaximum possible dosage, or in whom a side effect for whom a side effect could notallow the dose to be increased to its to its maximum allowed dose.

Exclusion

Exclusion Criteria:

  • Patient benefiting from a legal protection measure

  • Pregnant or breastfeeding woman

  • General and/or local infection (fistulous or cutaneous suppuration of the analmargin) in progress

  • Known neurological pathology that may explain the pain

  • Psychiatric pathology requiring a drug treatment treatment

  • Anticoagulants or haemostasis disorders

  • Hypersensitivity to lidocaine hydrochloride, to local anesthetics

  • Recurrent porphyrias

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Saline Solution for Block
Phase: 3
Study Start date:
December 08, 2023
Estimated Completion Date:
March 08, 2029

Study Description

Like carpal tunnel syndrome, pudendal neuralgia (PN) is defined as a syndrome of chronic nerve compression (of the pudendal nerve) causing neuropathic pain.

Treatment of NP is based on 3 therapeutic strategies of increasing aggressiveness: drug treatment, infiltrations and decompressive surgery.

Drug treatment is based on the "empirical" use of drugs for neuropathic pain that have proved effective in other areas (shingles, diabetes, etc.). People with this disease are generally considered 'non-responders' to drug treatment after failure (decrease in VAS scale < 3) of at least one antidepressant and one antiepileptic drug, whose doses have been increased to the maximum possible level, or in whom a side effect has prevented the dose from being increased to the maximum authorised level.

For pudendal nerve infiltration (ITNP), there is no consensus or recommendation on which molecules to use. Most studies have used a combination of local anaesthetics and corticosteroids. However, a randomised controlled trial, researchers compare lidocaine infiltration with or without methylprednisolone. The results were not significantly different (14% vs 11%).

According to the data in the literature, less than half of patients (11% to 39%) are relieved in the short term, up to 3 months, and only about 10% (6.8% to 12.2%) are still relieved at 1 year. The only recognised risk factor for failure seems to be the duration of pain (more than 1 year). Other risk factors have been described in the literature, but only in one study and not in the others, such as gender (male or female), age (over or under 70), duration of pain (over or under 1 year), and whether the pain is bilateral or not.

In our department, patients are currently treated with lidocaine INTP under neurostimulation. Given the poor results in terms of efficacy and the strong psychological component in chronic pain pathologies, the investigators propose in this study to compare our usual treatment with placebo, since no type of infiltration has ever been compared with placebo, although this is a condition where the placebo effect is likely to be large.

Connect with a study center

  • Hôpital Croix Saint-Simon

    Paris, 75020
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.